目的 探究匹多莫德口服液聯(lián)合蒲地蘭消炎口服液治療兒童手足口病的臨床療效。方法 選取2014年5月-2016年5月在首都醫(yī)科大學(xué)附屬北京同仁醫(yī)院治療的手足口病兒童患者84例，隨機(jī)分為對(duì)照組和治療組，每組各42例。對(duì)照組患兒口服蒲地蘭消炎口服液，1歲以下5 mL/次，1～3歲6.7 mL/次，3歲以上10 mL/次，3次/d。治療組患兒在對(duì)照組的基礎(chǔ)上口服匹多莫德口服液，400 mg/次，2次/d。兩組患兒均連續(xù)治療6 d。比較兩組患兒臨床療效、總病程時(shí)間、體征平均消失時(shí)間及治療前后血常規(guī)和血清C反應(yīng)蛋白（CRP）變化。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為88.10%、97.62%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者的總病程時(shí)間和各種病癥消失時(shí)間均顯著短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者白細(xì)胞（WBC）、中性粒細(xì)胞（GRAN）、肌酸激酶（CK）和CRP水平均顯著接近正常值，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組患者血常規(guī)和血清CRP改善程度優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 匹多莫德口服液聯(lián)合蒲地蘭消炎口服液對(duì)兒童手足口病具有更高的有效率和改善效果，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical value of Pidotimod Oral Solution combined with Pudilan Antiphlogistic Oral Liquid in treatment of children with hand-foot-and-mouth disease. Method Children (84 cases) with hand-foot-and-mouth disease in Beijing Tongren Hospital, CMU from May 2014 to May 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Children in the control group were po administered with Pudilan Antiphlogistic Oral Liquid, 5 mL/time for under 1 year old children, 6.7 mL/time for 1-3 years old children, and 10 mL/time for over 3 years old children, three times daily. Children in the treatment group were po administered with Pidotimod Oral Solution on the basis of the control group, 400 mg/time, twice daily. Children in two groups were treated for 6 d. After treatment, the clinical efficacy, total disease course, average disappearance time of symptoms, and change of blood routine and serum CRP in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.10% and 97.62%, respectively, and there was difference between two groups (P<0.05). After treatment, the total disease course and the average disappearance time of symptoms in the treatment were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, WBC, GRAN, CK, and CRP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood routine and serum CRP in the treatment were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pidotimod Oral Solution combined with Pudilan Antiphlogistic Oral Liquid has a higher efficiency and improved effect in treatment of children with hand-foot-and-mouth disease, which has a certain clinical application value.